Increased expression of Sestrin 2 in human and experimental heart failure

Menglong Wang,Jianfang Liu,Juanjuan Qin,Menglin Liu,Ying Feng,Lei Shi,Wenhui Yuan,Jing Ye,Jun Wan
2016-01-01
Abstract:Background: Sestrins (Sesns) are originally identified as critical antioxidant proteins and involved in complex regulation of cell viability in response to diverse stress conditions. However, the exact expression and function of Sesns in heart failure (HF) remains unclear. Methods and results: Sesns expression was detected in heart samples from end-stage HF patients and unmatched donors by real-time polymerase chain reaction (RT-PCR), Western Blotting and Immunofluorescence. Mice myocardial ischemia/ reperfusion (I/R) and myocardial infarction (MI) models and doxorubicin induced rat HF model were established to confirm the heart expression of Sesns. Sesn2 was significantly increased, whereas, no alteration for Sesn1 or Sesn3 in failing hearts when comparing with control hearts. Unexpectedly, the mRNA expression of Sesn2 in ischemic cardiomyopathy was higher than that in dilated cardiomyopathy. Immunofluorescence staining revealed all Sesns were expressed in non-cardiomyocytes in human heart. Furthermore, Sesn2 was co-expressed with vimentin, a marker for fibroblasts. Correlation analysis demonstrated Sesn2 levels were significantly correlated with expression levels of natriuretic peptide B (NPPB) and connective tissue growth factor (CTGF), markers for severity of HF and cardiac fibrosis. Meanwhile, the increased Sesn2 was validated in mice I/R and MI models, and also in doxorubicin induced rat HF model. Conclusions: Sesn2, which is expressed in cardiac fibroblasts, could be a potential biomarker to reflect the severity of HF and might play an important role during cardiac remodeling.
What problem does this paper attempt to address?